

Express Mail No. EV668295110US

Date of Deposit: August 24, 2006

PATENT

SLR:dm 08/23/06 6395-68026-07 566792 I-036-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hodge et al.**Application No.** _____**Filed:** Herewith**Confirmation No.** _____**For:** RAB9A, RAB11A, AND MODULATORS
THEREOF RELATED TO INFECTIOUS
DISEASE**Examiner:** Not yet assigned**Art Unit:** Not yet assigned**Attorney Reference No.** 6395-68026-07COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450**INFORMATION DISCLOSURE STATEMENT**
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

10/590844

IAP12 Rec'd PCT/PTO 24 AUG 2006

Express Mail No. EV668295110US

Date of Deposit: August 24, 2006


PATENT

SLR:dm 08/23/06 6395-68026-07 566792 I-036-04

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	6395-68026-07
	Application Number	
	Filing Date	August 24, 2006
	First Named Inventor	Hodge
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 2004/070002 A2	08/19/2004	The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Blot et al., "Targeting of the Human Immunodeficiency Virus Type 1 Envelope to the trans-Golgi Network through Binding to TIP47 is Required for Env Incorporation into Virions and Infectivity," <i>J. Virol.</i> 77:6931-6945 (2003).
		Chen et al., "High Resolution Crystal Structure of Human Rab9 GTPase," <i>J. Biol. Chem.</i> 279:40204-40208 (2004).
		Murray et al., "Rab9 GTPase is Required for Replication of Human Immunodeficiency Virus Type 1, Filoviruses, and Measles Virus," <i>J. Virol.</i> 79:11742-11751 (2005).
		Zhang et al., "Inhibition of Respiratory Syncytial Virus Infection with Intranasal siRNA Nanoparticles Targeting the Viral NS1 Gene," <i>Nature Med.</i> 11:56-62 (2005).

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	